Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10 - 29; http://dx.doi.org/10.3322/caac.20138; PMID: 22237781
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893 - 917; http://dx.doi.org/10.1002/ijc.25516; PMID: 21351269
   PubMed Web of Science ®Google Scholar
• Pound CR, Brawer MK, Partin AW. Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer. Rev Urol 2001; 3:72 - 84; PMID: 16985694
   PubMedGoogle Scholar
• Killian CS, Emrich LJ, Vargas FP, Yang N, Wang MC, Priore RL, et al. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. J Natl Cancer Inst 1986; 76:179 - 85; PMID: 2418245
   PubMed Web of Science ®Google Scholar
• Grossmann M, Zajac JD. Management of side effects of androgen deprivation therapy. [x.] Endocrinol Metab Clin North Am 2011; 40:655 - 71, x; http://dx.doi.org/10.1016/j.ecl.2011.05.004; PMID: 21889727
   PubMed Web of Science ®Google Scholar
• Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994; 151:622 - 8; PMID: 8308972
   PubMed Web of Science ®Google Scholar
• Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997; 159:3113 - 7; PMID: 9317107
   PubMed Web of Science ®Google Scholar
• Vuk-Pavlović S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, et al. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate 2010; 70:443 - 55; PMID: 19902470
   PubMed Web of Science ®Google Scholar
• Lowe D, Jorizzo J, Hutt MS. Tumour-associated eosinophilia: a review. J Clin Pathol 1981; 34:1343 - 8; http://dx.doi.org/10.1136/jcp.34.12.1343; PMID: 7035499
   PubMed Web of Science ®Google Scholar
• Samoszuk M. Eosinophils and human cancer. Histol Histopathol 1997; 12:807 - 12; PMID: 9225164
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brünner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999; 189:487 - 95; http://dx.doi.org/10.1002/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-I; PMID: 10629548
   PubMed Web of Science ®Google Scholar
• Dorta RG, Landman G, Kowalski LP, Lauris JR, Latorre MR, Oliveira DT. Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology 2002; 41:152 - 7; http://dx.doi.org/10.1046/j.1365-2559.2002.01437.x; PMID: 12147093
   PubMed Web of Science ®Google Scholar
• Ownby HE, Roi LD, Isenberg RR, Brennan MJ. Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer 1983; 52:126 - 30; http://dx.doi.org/10.1002/1097-0142(19830701)52:1<126::AID-CNCR2820520123>3.0.CO;2-Y; PMID: 6850535
   PubMed Web of Science ®Google Scholar
• Goldsmith MM, Belchis DA, Cresson DH, Merritt WD 3rd, Askin FB. The importance of the eosinophil in head and neck cancer. Otolaryngol Head Neck Surg 1992; 106:27 - 33; PMID: 1734363
   PubMed Web of Science ®Google Scholar
• Dalal BI, Das KC, Dutta TK, Malakar K. Local and systemic eosinophilia in patients with carcinoma of the uterine cervix undergoing radiation therapy: correlation with radiation response. Clinical oncology (Royal College of Radiologists (Great Britain)) 1992;4:18-21.
   Google Scholar
• Bethwaite PB, Holloway LJ, Yeong ML, Thornton A. Effect of tumour associated tissue eosinophilia on survival of women with stage IB carcinoma of the uterine cervix. J Clin Pathol 1993; 46:1016 - 20; http://dx.doi.org/10.1136/jcp.46.11.1016; PMID: 8254087
   PubMed Web of Science ®Google Scholar
• Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, Foster P, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. J Exp Med 2003; 197:387 - 93; http://dx.doi.org/10.1084/jem.20021683; PMID: 12566422
   PubMed Web of Science ®Google Scholar
• van Haelst Pisani C, Kovach JS, Kita H, Leiferman KM, Gleich GJ, Silver JE, et al. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood 1991; 78:1538 - 44; PMID: 1884020
   PubMed Web of Science ®Google Scholar
• Burch PA, Breen JK, Buckner JC, Gastineau DA, Kaur JA, Laus RL, et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6:2175 - 82; PMID: 10873066
   PubMed Web of Science ®Google Scholar
• Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004; 60:197 - 204; http://dx.doi.org/10.1002/pros.20040; PMID: 15176049
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894 - 903; PMID: 11099318
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089 - 94; http://dx.doi.org/10.1200/JCO.2005.04.5252; PMID: 16809734
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012; 104:273 - 9; http://dx.doi.org/10.1093/jnci/djr514; PMID: 22232132
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al, Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437 - 46; http://dx.doi.org/10.1016/S0140-6736(10)60172-9; PMID: 20398925
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324:787 - 90; http://dx.doi.org/10.1126/science.1168175; PMID: 19359544
   PubMed Web of Science ®Google Scholar
• Pal SK, Sartor O. Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer. Maturitas 2011; 68:103 - 5; http://dx.doi.org/10.1016/j.maturitas.2010.10.009; PMID: 21093995
   PubMed Web of Science ®Google Scholar
• Martin JM, Supiot S, Berthold DR. Pharmacotherapeutic management of locally advanced prostate cancer: current status. Drugs 2011; 71:1019 - 41; http://dx.doi.org/10.2165/11591500-000000000-00000; PMID: 21668040
   PubMed Web of Science ®Google Scholar